AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37486372
Drug: Endoscopic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapy combined with partial splenic embolization (EP group)
Trial: 37486372
Drug: Endoscopic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic therapy alone (E group)
Trial: 37486633
Drug: Mailed nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mailed nicotine patches
Trial: 37486650
Drug: Intravenous Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Iron supplementation
Trial: 37486650
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Iron supplementation
Trial: 37486652
Drug: Cabergoline 1
RxNorm normalized name: cabergoline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 1 mg once
Trial: 37486775
Drug: Pitavastatin calcium
RxNorm normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin calcium 4 mg daily
Trial: 37486952
Drug: Micronutrient-fortified balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient-fortified balanced energy-protein (BEP) supplementation and iron-folic acid (IFA) tablets
Trial: 37487144
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant therapy in PORTEC-1 trial
Trial: 37487169
Drug: Atezolizumab (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1,200 mg) once every 3 weeks
Trial: 37487169
Drug: Atezolizumab (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1,200 mg) once every 3 weeks + Radiotherapy (RT)
Trial: 37488191
Drug: Samuraciclib (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samuraciclib (360 mg once daily)
Trial: 37488191
Drug: Samuraciclib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samuraciclib monotherapy in TNBC
Trial: 37488191
Drug: Samuraciclib in
RxNorm normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samuraciclib in combination with fulvestrant
Trial: 37488287
Drug: Neoadjuvant PD-L1
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant PD-L1 blockade with adebrelimab (two doses before surgery)
Trial: 37488446
Drug: 2-OHOA (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-OHOA (sodium 2-hydroxyoleate) at a maximum tolerated dose (MTD) of 12,000 mg/daily
Trial: 37488580
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta infusions <90 min
Trial: 37488580
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta infusions ≥90 min
Trial: 37488580
Drug: Infusion rates
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion rates
Trial: 37488580
Drug: Anti-agalsidase beta
RxNorm normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anti-agalsidase beta antibody-positive patients
Trial: 37488588
Drug: MT-assisted ambulation
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-assisted ambulation up to three times daily, guided by the Johns Hopkins Mobility Goal Calculator, until hospital discharge or after 10 days.
Trial: 37488627
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two treatments (from the above options)
Trial: 37488627
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment (from the above options)
Trial: 37488734
Drug: holo beta-lactoglobulin
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: holo beta-lactoglobulin lozenge (holoBLG) 2x daily for 3 months
Trial: 37488811
Drug: Risankizumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (150 mg at weeks 0 and 4)
Trial: 37489066
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg, tremelimumab 75 mg, cisplatin 80 mg/m²
Trial: 37489066
Drug: Durvalumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab with tremelimumab and chemotherapy
Trial: 37489819
Drug: FDA approved
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved drugs matched to genomic targets
Trial: 37489819
Drug: FDA approved
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved drugs used outside their approved indications
Trial: 37490017
Drug: Usual territorial
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual territorial rehabilitative treatments (UTRTs; control group)
Trial: 37490085
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin (90 mg/kg/d) and clavulanate (6.4 mg/kg/d) for 10 days (n=254)
Trial: 37490085
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin and clavulanate
Trial: 37490337
Drug: Digital physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital physical therapy (home exercise, education, CBT, device with movement digitalization, asynchronous monitoring)
Trial: 37490337
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (in-person exercises, manual therapy, education, CBT)
Trial: 37490604
Drug: Flavored polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavored polyethylene glycol and sulfate solution (FPSS)
Trial: 37490939
Drug: Nano-curcumin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-curcumin (40 mg)
Trial: 37491084
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery relaxation therapy in the form of a leaflet plus standard care
Trial: 37491088
Drug: Daptomycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (10 mg/kg/d for 8 days)
Trial: 37491309
Drug: TAK-228 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 (4 mg) and TAK-117 (200 mg) orally each day for 3 days followed by 4 days off, weekly, until disease progression (PD)
Trial: 37491309
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2) and nab paclitaxel therapy post PIKTOR
Trial: 37491373
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOv18 IgE antibody (dose escalation from 70 μg to 12 mg)
Trial: 37491373
Drug: MOv18 IgE
RxNorm normalized name: IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOv18 IgE antibody
Trial: 37491568
Drug: OSA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSA treatment
Trial: 37491568
Drug: No OSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No OSA treatment or discontinued treatment
Trial: 37491889
Drug: Lurbinectedin +
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin + ATR inhibitor berzosertib
Trial: 37491938
Drug: zuranolone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zuranolone 50 mg/day
Trial: 37492087
Drug: Qiangli Dingxuan
RxNorm normalized name: Dingxiang
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qiangli Dingxuan tablet combined with amlodipine besylate
Trial: 37492633
Drug: Oral paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral paclitaxel (oPAC) with encequidar (E) administered at 205 mg/m
Trial: 37492635
Drug: Weekly reminders
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly reminders
Trial: 37492920
Drug: Ligelizumab 120
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligelizumab 120 mg
Trial: 37492970
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy with successful reperfusion (Thrombolysis in Cerebral Infarction score, 2b/3)
Trial: 37492970
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy with successful reperfusion at attempts 1
Trial: 37492970
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy with >2 recanalization attempts
Trial: 37492976
Drug: 5-ASA co-treatment
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA co-treatment
Trial: 37493020
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy for <12 months
Trial: 37493020
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy for 12 to <24 months
Trial: 37493020
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy for 24 to <36 months
Trial: 37493020
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy for ≥36 months
Trial: 37493020
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy for <36 months
Trial: 37493229
Drug: Vaginal probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal probiotic suppository
Trial: 37493229
Drug: Without vaginal
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Without vaginal probiotic suppository (Control)
Trial: 37493269
Drug: RSV/6120/ΔNS2/1030s vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV/6120/ΔNS2/1030s vaccine (105 PFU)
Trial: 37493287
Drug: Sham injections
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injections (sodium chloride 0.9%)
Trial: 37493759
Drug: Combination Training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Training (COMB)
Trial: 37493932
Drug: MedViewer (MV)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MedViewer (MV) intervention providing real-time adherence feedback using IR-MALDESI mass spectrometry imaging of daily ART concentrations in hair.
Trial: 37494014
Drug: Liraglutide, 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide, 3.0 mg, once daily
Trial: 37494101
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (1 mg/kg) as an adjunct to sedation protocol
Trial: 37494101
Drug: Fentanyl (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1.5 mcg/kg) and midazolam (2 mg)
Trial: 37494942
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg), Emtricitabine (200 mg), Tenofovir Disoproxil Fumarate (300 mg)
Trial: 37495197
Drug: Deep artificial
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep artificial neural networks (DNNs) with data augmentation strategies
Trial: 37495197
Drug: Modern DNNs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern DNNs using augmentation
Trial: 37495274
Drug: Subcutaneous Implantable
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD)
Trial: 37495276
Drug: Combination lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination lipid-lowering therapy (rosuvastatin 10 mg plus ezetimibe 10 mg)
Trial: 37496004
Drug: Afamelanotide 16
RxNorm normalized name: afamelanotide 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afamelanotide 16 mg implants administered subcutaneously on Day 0, Day 1, and repeated on Day 7 and Day 8 if not well recovered.
Trial: 37496004
Drug: Afamelanotide 16
RxNorm normalized name: afamelanotide 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afamelanotide 16 mg implants administered subcutaneously.
Trial: 37496298
Drug: parsaclisib 20
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parsaclisib 20 mg once daily for 8 weeks, followed by 20 mg once weekly thereafter, in combination with obinutuzumab and bendamustine
Trial: 37496411
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs)
Trial: 37496612
Drug: Adintrevimab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adintrevimab (300 mg intramuscular injection)
Trial: 37497167
Drug: Parenteral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Parenteral treprostinil initiated at 2 ng/kg/min intravenously or subcutaneously, with up-titration determined by clinicians
Trial: 37497167
Drug: Rapid cross-titration
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rapid cross-titration in an inpatient setting (median: 2 days)
Trial: 37497167
Drug: Gradual cross-titration
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gradual cross-titration in an outpatient setting (median: 5 days)
Trial: 37497337
Drug: IRS-Low (IRS-L)
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRS-Low (IRS-L)
Trial: 37497337
Drug: IRS-Ultra-Low (IRS-UL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRS-Ultra-Low (IRS-UL) with chemotherapy
Trial: 37497337
Drug: IRS-H with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRS-H with anti-PD-(L)1
Trial: 37497354
Drug: Family-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive behavioral therapy (FCBT)
Trial: 37497372
Drug: High-definition transcranial
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-definition transcranial direct current stimulation (HD-tDCS) over the primary motor cortex (M1), 10 daily sessions of 20 minutes each.
Trial: 37497398
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose statins use (0.6% reported use, 212 individuals)
Trial: 37497816
Drug: Compression with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression with deferred endovenous treatment
Trial: 37497888
Drug: SLN124 (1.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLN124 (1.0, 3.0, and 4.5 mg/kg)
Trial: 37497921
Drug: Combination chemoimmunotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemoimmunotherapy and targeted treatment
Trial: 37497921
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies (chemoimmunotherapy or targeted combinations)
Trial: 37497921
Drug: CLL Treatment-Infection
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CLL Treatment-Infection Model (machine learning-based algorithm)
Trial: 37498105
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of silkworm pupae extract (SWP) per day plus regular exercise (n=27)
Trial: 37498596
Drug: Fosaprepitant weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant weekly
Trial: 37498661
Drug: Online Public
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online Public Health Nurse-Delivered Group Cognitive Behavioral Therapy
Trial: 37498821
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus up to 16 sessions of physical therapy
Trial: 37499521
Drug: Binimetinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib plus erlotinib (erlotinib 100 mg daily and binimetinib 15 mg BID × 5 days/week)
Trial: 37499670
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily
Trial: 37499679
Drug: Pfs230D1-EPA/Alhydrogel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs230D1-EPA/Alhydrogel (40 μg)
Trial: 37499679
Drug: Pfs25-EPA/Alhydrogel (47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25-EPA/Alhydrogel (47 μg)
Trial: 37499679
Drug: Pfs25-EPA/Alhydrogel (47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25-EPA/Alhydrogel (47 μg) plus Pfs230D1-EPA/Alhydrogel (40 μg)
Trial: 37500612
Drug: 3-weeks induction
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weeks induction insulin therapy (glargine/lispro) followed by metformin maintenance with intermittent 2-week courses of insulin every 3-months for 2-years
Trial: 37500612
Drug: 3-weeks induction
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weeks induction insulin therapy (glargine/lispro) followed by metformin maintenance
Trial: 37501016
Drug: gavo-cel (T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gavo-cel (T cell receptor fusion construct) administered as a single agent (n=3) or after lymphodepletion (n=29)
Trial: 37501016
Drug: gavo-cel (T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gavo-cel (T cell receptor fusion construct)
Trial: 37501180
Drug: Low-threshold HCV
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-threshold HCV treatment model at a syringe services program
Trial: 37502440
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of UCA1, WRAP53, and serum α-fetoprotein (AFP)
Trial: 37502622
Drug: AK0529 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK0529 2 mg/kg bid
Trial: 37503157
Drug: Blood biomarker
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood biomarker panel (kidney injury molecule-1, N-terminal pro-B-type natriuretic peptide, osteopontin, and tissue inhibitor of metalloproteinase-1)
Trial: 37503561
Drug: Anti-RBD IgG
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-RBD IgG concentrations ≥1000 BAU/mL
Trial: 37503561
Drug: Anti-RBD IgG
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-RBD IgG concentrations ≥3000 BAU/mL
Trial: 37503661
Drug: Encoberminogene rezmadenovec
RxNorm normalized name: Aglatimagene besadenovec
DrugBank: Aglatimagene besadenovec (DB15074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encoberminogene rezmadenovec (XC001) administered via epicardial delivery
Trial: 37504371
Drug: Poor chemotherapy-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor chemotherapy-induced tumor necrosis
Trial: 37506264
Drug: Investigator-assigned standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator-assigned standard therapy (IAT)
Trial: 37506339
Drug: RD maintenance
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RD maintenance therapy
Trial: 37506557
Drug: T-cell vaccine
RxNorm normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell vaccine combined with romidepsin (RMD)
Trial: 37506557
Drug: Anti-CD33 antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CD33 antibody
Trial: 37506599
Drug: Lacticaseibacillus paracasei
RxNorm normalized name: Lacticaseibacillus paracasei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacticaseibacillus paracasei 8700:2 (10 billion CFU) daily for 12 weeks